The growth of the global AI in drug discovery market is driven by various factors such as investments by industry giants into the AI business, increasing number of startups operating in AI spectrum for healthcare including drug discovery, machine learning, and other AI technologies and increased use of AI technology by major pharma companies in the drug discovery. AI in Drug Discovery Market is expected to hold a value of about USD 8.9 Billion by 2030, and it is projected to register a CAGR of 24.9% from 2022 to 2030. In addition, the increasing number of cross-industry partnerships for achieving the common goal of improvement in the drug development outcomes is another factor for the growth of the AI in the drug discovery market. Below is the chart representing the number of AI-driven deals each of the Big Biopharma companies have disclosed till March 2019.